Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2020 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients Undergoing Renal Transplantation

University Hospital of Nantes will sponsor and conduct the clinical trialOSE Immunotherapeutics will provide its FR104 productPost-transplant immune response is a key therapeutic issue for patients...
November 09, 2020 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics to Present at SITC Annual Meeting and at Additional International Immuno-Oncology Summits

NANTES, France, Nov. 09, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) has been invited to provide an update on its R&D programs in immuno-oncology at several...
November 05, 2020 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Provides COVID-19 Vaccine Update on CoVepiT, its Multi-Target and Long-Lasting Vaccine Candidate

Primary Objective Achieved in Human Ex Vivo StudyNew Coronavirus Mutated Variants Strengthen the Multi-Epitope T Lymphocytes Vaccine Versus 11 Viral Proteins ApproachClinical Trial Expected to Start...
October 30, 2020 02:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation

NANTES, France, Oct. 30, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) presented preclinical efficacy data for novel agonist monoclonal antibody therapy, OSE-230,...
October 22, 2020 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Publication Supporting Additional New Mechanism of Action for Selective Antibody Antagonist of SIRPα BI 765063 in the Journal of Clinical Investigation

NANTES, France, Oct. 22, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced a publication in the prestigious Journal of Clinical Investigation (JCI) of...
October 12, 2020 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives European Patent Notice of Allowance for First-in-Class CD28-Antagonist Immunotherapy FR104

NANTES, France, Oct. 12, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announced the European Patent Office’s (EPO) issuance of a notice of allowance for its...
September 21, 2020 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi® in NSCLC at the European Society for Medical Oncology Virtual Congress 2020

NANTES, France, Sept. 21, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) presented positive results from Step-1 of its Phase 3 trial of neoepitope-based cancer...
September 17, 2020 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Reports First Half 2020 Results and Corporate Update

Positive results for Step-1 of Phase 3 clinical trial of Tedopi® in non-small cell lung cancerPositive preclinical and in human ex vivo results with CoVepiT vaccine against COVID-19; clinical entry...
September 08, 2020 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference September 14 - 16, 2020 (Virtual Conference)

NANTES, France, Sept. 08, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced it will present at the H.C. Wainwright 22nd Annual Global Investment...
August 17, 2020 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results With Multi-Target Vaccine CoVepiT

Data support potential as novel and differentiated COVID-19 vaccine designed against multiple SARS-CoV-2 targets with technology known to induce memory T lymphocytesStudies show that CoVepiT provides...